# A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT00861874** · PHASE1 · COMPLETED · sponsor: **University of Rochester** · enrollment: 13 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Rapamycin

## Key facts

- **NCT ID:** NCT00861874
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2012-09
- **Final completion:** —
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2012-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00861874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00861874, "A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00861874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*